Compare TRN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRN | IDYA |
|---|---|---|
| Founded | 1933 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 1994 | 2019 |
| Metric | TRN | IDYA |
|---|---|---|
| Price | $33.53 | $29.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $34.00 | ★ $52.86 |
| AVG Volume (30 Days) | 545.4K | ★ 809.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 85.98 | 61.90 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,156,900,000.00 | $218,710,000.00 |
| Revenue This Year | $1.91 | N/A |
| Revenue Next Year | $15.61 | $201.05 |
| P/E Ratio | $110.58 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $22.38 | $18.26 |
| 52 Week High | $37.36 | $39.28 |
| Indicator | TRN | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 50.70 |
| Support Level | $27.09 | $29.51 |
| Resistance Level | $35.33 | $31.07 |
| Average True Range (ATR) | 1.32 | 1.14 |
| MACD | -0.29 | 0.17 |
| Stochastic Oscillator | 25.15 | 93.36 |
Trinity Industries Inc sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in two main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.